TherapeuticsMD Inc (NYSEMKT:TXMD) was upgraded by research analysts at Oppenheimer Holdings, Inc. from a “market perform” rating to an “outperform” rating in a note issued to investors on Tuesday, StockTargetPrices.com reports.

Several other brokerages have also commented on TXMD. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a research note on Thursday, May 25th. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 price target on shares of TherapeuticsMD in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $20.57.

TherapeuticsMD (TXMD) traded up 8.12% during midday trading on Tuesday, hitting $5.19. The stock had a trading volume of 3,049,874 shares. The firm has a 50-day moving average of $4.62 and a 200-day moving average of $5.62. The company’s market cap is $1.06 billion. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.39.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/11/therapeuticsmd-inc-txmd-raised-to-outperform-at-oppenheimer-holdings-inc.html.

Several institutional investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. bought a new position in TherapeuticsMD during the fourth quarter worth $106,000. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of TherapeuticsMD by 20.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $128,000 after buying an additional 3,740 shares during the period. Guggenheim Capital LLC increased its stake in shares of TherapeuticsMD by 135.9% in the fourth quarter. Guggenheim Capital LLC now owns 36,290 shares of the specialty pharmaceutical company’s stock worth $209,000 after buying an additional 20,904 shares during the period. Norges Bank acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth about $8,261,000. Finally, State Street Corp increased its stake in shares of TherapeuticsMD by 9.1% in the fourth quarter. State Street Corp now owns 3,650,254 shares of the specialty pharmaceutical company’s stock worth $21,064,000 after buying an additional 303,633 shares during the period.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Stock Target Prices

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.